BackFidelity Select Biotechnology Portfolio Overview

Fidelity Select Biotechnology Portfolio Operating Income

Track Fidelity Select Biotechnology Portfolio's operating income ($8.3M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly Operating Income

$2.08M
3.24% YoY

As of Sep 30, 2023

Annual Operating Income (TTM)

$8.27M
10.66% YoY

Trailing 12 months ending Sep 30, 2023

Average Operating Income (Comparison Companies)

Operating Income History

Operating Income Comparison

Annual Operating Income Growth Rate (%)

Annual Operating Income Growth (Absolute)

Fidelity Select Biotechnology Portfolio (FBIOX) FAQ

As of the most recent data (September 2023), FBIOX shows a operating income of $8.3M. That compares with $7.5M in the prior-year period — up 10.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, FBIOX's operating income is now $8.3M (was $7.5M) — a 10.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Fidelity Select Biotechnology Portfolio is outperforming or lagging.

Tracking FBIOX's operating income over time shows whether Fidelity Select Biotechnology Portfolio is scaling, shrinking, or reshaping that part of the business. The current reading is $8.3M That compares with $7.5M in the prior-year period — up 10.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Fidelity Select Biotechnology Portfolio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $8.3M) with ownership activity and broader fundamentals.